Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The human vaginal microbiome is a complex, dynamic community of microorganisms—primarily bacteria—inhabiting the vaginal tract. The ecosystem is dominated in healthy reproductive-age women by *Lactobacillus* species, which help maintain acidic pH and offer protection against pathogenic infections and inflammation. Dysbiosis, marked by loss or reduction of *Lactobacillus* and overgrowth of other taxa (e.g., *Gardnerella*, *Prevotella*), is associated with increased risks of bacterial vaginosis, candidiasis, sexually transmitted infections, and adverse reproductive outcomes. Several therapeutic and diagnostic approaches—including antibiotics, probiotics, and advanced sequencing for profiling—are employed to manage and investigate vaginal microbiome-related health and disease.
Restoration of *Lactobacillus* dominance (for probiotics and transplantation); Eradication of overgrown pathogens (for antibiotics/antifungals); Rebalance of microbial communities (for live biotherapeutic products)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human vaginal microbiome.